Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1963 2
1964 2
1965 1
1966 1
1967 3
1968 1
1969 7
1970 3
1972 3
1973 1
1974 1
1975 4
1976 2
1977 1
1978 4
1979 5
1980 3
1981 4
1982 7
1983 5
1984 4
1985 7
1986 19
1987 11
1988 18
1989 21
1990 24
1991 21
1992 31
1993 16
1994 15
1995 24
1996 25
1997 22
1998 19
1999 22
2000 32
2001 25
2002 21
2003 27
2004 21
2005 27
2006 10
2007 17
2008 25
2009 25
2010 14
2011 18
2012 28
2013 33
2014 39
2015 39
2016 42
2017 40
2018 37
2019 35
2020 35
2021 31
2022 33
2023 31
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

976 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socié G; International PNH Interest Group. Parker C, et al. Among authors: nishimura j. Blood. 2005 Dec 1;106(12):3699-709. doi: 10.1182/blood-2005-04-1717. Epub 2005 Jul 28. Blood. 2005. PMID: 16051736 Free PMC article. Review. No abstract available.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Among authors: nishimura ji. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. Röth A, et al. Among authors: nishimura ji. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. Blood. 2020. PMID: 31978221 Free PMC article. Clinical Trial.
Commentary: Tick-tock.
Nishimura J, Mokadam NA. Nishimura J, et al. J Thorac Cardiovasc Surg. 2021 Jul;162(1):68-69. doi: 10.1016/j.jtcvs.2020.01.027. Epub 2020 Jan 31. J Thorac Cardiovasc Surg. 2021. PMID: 32087953 Free article. No abstract available.
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Among authors: nishimura ji. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Saito T, et al. Among authors: nishimura j. Nat Med. 2016 Jun;22(6):679-84. doi: 10.1038/nm.4086. Epub 2016 Apr 25. Nat Med. 2016. PMID: 27111280
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Lee JW, et al. Among authors: nishimura ji. Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0. Lancet Haematol. 2023. PMID: 38030318 Clinical Trial.
[Drug-induced hematological disorders].
Nishimura J, Motomura S, Akagi T. Nishimura J, et al. Nihon Rinsho. 2007 Oct 28;65 Suppl 8:99-105. Nihon Rinsho. 2007. PMID: 18074523 Review. Japanese. No abstract available.
976 results